

Diabetic Foot Ulcers Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/DE94C70C8BDBEN.html>

Date: May 2024

Pages: 134

Price: US\$ 6,499.00 (Single User License)

ID: DE94C70C8BDBEN

Abstracts

The 7 major diabetic foot ulcers markets reached a value of US\$ 3.5 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 5.4 Billion by 2034, exhibiting a growth rate (CAGR) of 3.96% during 2024-2034.

The diabetic foot ulcers market has been comprehensively analyzed in IMARC's new report titled "Diabetic Foot Ulcers Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Diabetic foot ulcers are a common complication of diabetes that occurs when there is damage to the nerves and blood vessels in the feet. This condition can reduce blood flow and decrease sensation in the feet, making them more vulnerable to injury, open sores, or wounds and slower to heal. The common indications of the ailment include swelling, large calluses or cracked heels, blisters, redness, sores, splinters, scrapes, pus, etc. The diagnosis of diabetic foot ulcers is typically made by a review of the patient's medical history, clinical features, and swab tests for secondary infection. Numerous laboratory investigations, including fasting blood sugar, a complete metabolic panel, glycated hemoglobin levels, erythrocyte sedimentation rate, a complete blood count, C-reactive protein, etc., are also utilized to confirm a diagnosis. The healthcare provider may perform X-rays among patients to evaluate the involvement of the bone.

The rising cases of chronic diabetes due to poor glycemic control coupled with the increasing unmet need for effective drugs to address this illness are primarily driving the diabetic foot ulcers market. Furthermore, the growing prevalence of several associated risk factors, such as foot deformities, ill-fitting footwear, underlying peripheral neuropathy, improper foot care, inadequate blood circulation, dry skin, etc., is also propelling the market growth. In addition to this, the escalating utilization of negative-

pressure wound therapy, which uses sub-atmospheric pressure to minimize inflammatory exudate and encourage granulation tissue to optimize the physiology involved in wound healing, is creating a positive outlook for the market. Moreover, the inflating adoption of granulocyte-colony stimulating factors (G-CSF) for treating this ailment, since they improve clinical outcomes in patients by increasing the release of neutrophils from the bone marrow and enhancing their function, is also bolstering the market growth. Apart from this, the emerging popularity of tissue-engineered skin substitutes that are designed using living cells, like fibroblasts, keratinocytes, stem cells, etc., to replace or supplement damaged skin and promote wound healing is expected to drive the diabetic foot ulcers market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the diabetic foot ulcers market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for diabetic foot ulcers and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the diabetic foot ulcers market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the diabetic foot ulcers market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the diabetic foot ulcers market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current diabetic foot ulcers marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the diabetic foot ulcers market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the diabetic foot ulcers market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the diabetic foot ulcers market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (?2018-2034?) of diabetic foot ulcers across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of diabetic foot ulcers by age across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of diabetic foot ulcers by gender across the seven major markets?

How many patients are diagnosed (?2018-2034?) with diabetic foot ulcers across the seven major markets?

What is the size of the diabetic foot ulcers patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of diabetic foot ulcers?

What will be the growth rate of patients across the seven major markets?

Diabetic Foot Ulcers: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for diabetic foot ulcers drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the diabetic foot ulcers market?

What are the key regulatory events related to the diabetic foot ulcers market?

What is the structure of clinical trial landscape by status related to the diabetic foot ulcers market?

What is the structure of clinical trial landscape by phase related to the diabetic foot ulcers market?

What is the structure of clinical trial landscape by route of administration related to the diabetic foot ulcers market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 DIABETIC FOOT ULCERS - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 DIABETIC FOOT ULCERS - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 DIABETIC FOOT ULCERS - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (?2018-2034?)
 - 7.2.4 Epidemiology by Gender (?2018-2034?)
 - 7.2.5 Diagnosed Cases (?2018-2034?)
 - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (?2018-2034?)
 - 7.3.4 Epidemiology by Gender (?2018-2034?)
 - 7.3.5 Diagnosed Cases (?2018-2034?)
 - 7.3.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (?2018-2034?)
 - 7.4.4 Epidemiology by Gender (?2018-2034?)
 - 7.4.5 Diagnosed Cases (?2018-2034?)
 - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (?2018-2034?)
 - 7.5.4 Epidemiology by Gender (?2018-2034?)
 - 7.5.5 Diagnosed Cases (?2018-2034?)
 - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (?2018-2034?)
 - 7.6.4 Epidemiology by Gender (?2018-2034?)
 - 7.6.5 Diagnosed Cases (?2018-2034?)
 - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (?2018-2034?)

- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (?2018-2034?)
 - 7.8.4 Epidemiology by Gender (?2018-2034?)
 - 7.8.5 Diagnosed Cases (?2018-2034?)
 - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (?2018-2034?)
 - 7.9.4 Epidemiology by Gender (?2018-2034?)
 - 7.9.5 Diagnosed Cases (?2018-2034?)
 - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

8 DIABETIC FOOT ULCERS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 DIABETIC FOOT ULCERS - UNMET NEEDS

10 DIABETIC FOOT ULCERS - KEY ENDPOINTS OF TREATMENT

11 DIABETIC FOOT ULCERS - MARKETED PRODUCTS

- 11.1 List of Diabetic Foot Ulcers Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Regranex (Becaplermin gel) - Johnson & Johnson
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets
 - 11.1.2 Zyvox (Linezolid) - Pfizer
 - 11.1.2.1 Drug Overview

- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets
- 11.1.3 Fespixon (Centella Asiatica extract) - Oneness Biotech
 - 11.1.3.1 Drug Overview
 - 11.1.3.2 Mechanism of Action
 - 11.1.3.3 Regulatory Status
 - 11.1.3.4 Clinical Trial Results
 - 11.1.3.5 Sales Across Major Markets
- 11.1.4 Easyef (Nepidermin) - Daewoong Pharmaceutical
 - 11.1.4.1 Drug Overview
 - 11.1.4.2 Mechanism of Action
 - 11.1.4.3 Regulatory Status
 - 11.1.4.4 Clinical Trial Results
 - 11.1.4.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 DIABETIC FOOT ULCERS - PIPELINE DRUGS

- 12.1 List of Diabetic Foot Ulcers Pipeline Drugs Across the Top 7 Markets
 - 12.1.1 APO2 - Aposcience
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action
 - 12.1.1.3 Clinical Trial Results
 - 12.1.1.4 Safety and Efficacy
 - 12.1.1.5 Regulatory Status
 - 12.1.2 AUP1602 C - Aurealis Pharma
 - 12.1.2.1 Drug Overview
 - 12.1.2.2 Mechanism of Action
 - 12.1.2.3 Clinical Trial Results
 - 12.1.2.4 Safety and Efficacy
 - 12.1.2.5 Regulatory Status
 - 12.1.3 Bisphosphocin Nu 3 - Lakewood-Amedex Inc
 - 12.1.3.1 Drug Overview
 - 12.1.3.2 Mechanism of Action
 - 12.1.3.3 Clinical Trial Results
 - 12.1.3.4 Safety and Efficacy

- 12.1.3.5 Regulatory Status
- 12.1.4 allo APZ2 DFU - RHEACELL
 - 12.1.4.1 Drug Overview
 - 12.1.4.2 Mechanism of Action
 - 12.1.4.3 Clinical Trial Results
 - 12.1.4.4 Safety and Efficacy
 - 12.1.4.5 Regulatory Status
- 12.1.5 MBN 101 - Microbion Corporation
 - 12.1.5.1 Drug Overview
 - 12.1.5.2 Mechanism of Action
 - 12.1.5.3 Clinical Trial Results
 - 12.1.5.4 Safety and Efficacy
 - 12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. DIABETIC FOOT ULCERS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. DIABETIC FOOT ULCERS – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 DIABETIC FOOT ULCERS - MARKET SCENARIO

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
 - 15.2.1 Diabetic Foot Ulcers - Market Size
 - 15.2.1.1 Market Size (2018-2023)
 - 15.2.1.2 Market Forecast (2024-2034)
 - 15.2.2 Diabetic Foot Ulcers - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2018-2023)
 - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
 - 15.3.1 Diabetic Foot Ulcers - Market Size
 - 15.3.1.1 Market Size (2018-2023)

- 15.3.1.2 Market Forecast (2024-2034)
- 15.3.2 Diabetic Foot Ulcers - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
- 15.3.3 Diabetic Foot Ulcers - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Diabetic Foot Ulcers - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Diabetic Foot Ulcers - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Diabetic Foot Ulcers - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Diabetic Foot Ulcers - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Diabetic Foot Ulcers - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (2024-2034)
 - 15.5.3 Diabetic Foot Ulcers - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Diabetic Foot Ulcers - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Diabetic Foot Ulcers - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Diabetic Foot Ulcers - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Diabetic Foot Ulcers - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Diabetic Foot Ulcers - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Diabetic Foot Ulcers - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Diabetic Foot Ulcers - Market Size

- 15.8.1.1 Market Size (2018-2023)
- 15.8.1.2 Market Forecast (2024-2034)
- 15.8.2 Diabetic Foot Ulcers - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
- 15.8.3 Diabetic Foot Ulcers - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Diabetic Foot Ulcers - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Diabetic Foot Ulcers - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Diabetic Foot Ulcers - Access and Reimbursement Overview

16 DIABETIC FOOT ULCERS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 DIABETIC FOOT ULCERS MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 DIABETIC FOOT ULCERS MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Diabetic Foot Ulcers Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/DE94C70C8BDBEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/DE94C70C8BDBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

